FI3157527T3 - Ezh2-inhibiittoreita lymfoman hoitoon - Google Patents
Ezh2-inhibiittoreita lymfoman hoitoon Download PDFInfo
- Publication number
- FI3157527T3 FI3157527T3 FIEP15809540.6T FI15809540T FI3157527T3 FI 3157527 T3 FI3157527 T3 FI 3157527T3 FI 15809540 T FI15809540 T FI 15809540T FI 3157527 T3 FI3157527 T3 FI 3157527T3
- Authority
- FI
- Finland
- Prior art keywords
- inhibitor
- ezh2
- use according
- bid
- nhl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 24
- 206010025323 Lymphomas Diseases 0.000 title claims 3
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 claims 17
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 claims 17
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 9
- 101000782464 Homo sapiens Zinc finger protein 444 Proteins 0.000 claims 6
- 102100035868 Zinc finger protein 444 Human genes 0.000 claims 6
- 101150090105 Ezh2 gene Proteins 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 210000001280 germinal center Anatomy 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical group C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462013522P | 2014-06-17 | 2014-06-17 | |
| US201462036265P | 2014-08-12 | 2014-08-12 | |
| PCT/US2015/036310 WO2015195848A1 (en) | 2014-06-17 | 2015-06-17 | Ezh2 inhibitors for treating lymphoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3157527T3 true FI3157527T3 (fi) | 2023-07-25 |
Family
ID=54936086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP15809540.6T FI3157527T3 (fi) | 2014-06-17 | 2015-06-17 | Ezh2-inhibiittoreita lymfoman hoitoon |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10166238B2 (enExample) |
| EP (2) | EP4252851A3 (enExample) |
| JP (1) | JP6779793B2 (enExample) |
| KR (2) | KR102497728B1 (enExample) |
| CN (2) | CN106999498B (enExample) |
| AU (3) | AU2015277139A1 (enExample) |
| BR (1) | BR112016029492A2 (enExample) |
| CA (1) | CA2952074C (enExample) |
| DK (1) | DK3157527T3 (enExample) |
| EA (1) | EA038337B1 (enExample) |
| ES (1) | ES2948442T3 (enExample) |
| FI (1) | FI3157527T3 (enExample) |
| HU (1) | HUE062158T2 (enExample) |
| IL (3) | IL309539A (enExample) |
| LT (1) | LT3157527T (enExample) |
| MX (2) | MX2021007651A (enExample) |
| PL (1) | PL3157527T3 (enExample) |
| PT (1) | PT3157527T (enExample) |
| SG (2) | SG11201610273VA (enExample) |
| SI (1) | SI3157527T1 (enExample) |
| WO (1) | WO2015195848A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2841142C (en) | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| KR20190105669A (ko) | 2012-10-15 | 2019-09-17 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| MX373187B (es) | 2013-12-06 | 2020-04-13 | Epizyme Inc | Terapia de combinación para tratar cáncer. |
| EA038337B1 (ru) | 2014-06-17 | 2021-08-11 | Эпизим, Инк. | Ингибиторы ezh2 для лечения лимфомы |
| CN106794177A (zh) * | 2014-10-16 | 2017-05-31 | Epizyme股份有限公司 | 治疗癌症的方法 |
| KR102964530B1 (ko) * | 2014-11-17 | 2026-05-13 | 에피자임, 인코포레이티드 | 암을 치료하기 위한 방법 |
| TW201636344A (zh) | 2014-12-05 | 2016-10-16 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| MX391720B (es) | 2015-04-20 | 2025-03-21 | Epizyme Inc | Terapia combinada para tratar cáncer. |
| EA201890009A1 (ru) | 2015-06-10 | 2018-07-31 | Эпизайм, Инк. | Ингибиторы ezh2 для лечения лимфомы |
| WO2017035234A1 (en) | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| US11951108B2 (en) | 2016-01-29 | 2024-04-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| US11786533B2 (en) | 2016-06-01 | 2023-10-17 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| US20190381025A1 (en) * | 2017-01-20 | 2019-12-19 | Constellation Pharmaceuticals, Inc. | Solid dispersions of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
| WO2018183885A1 (en) | 2017-03-31 | 2018-10-04 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2018275123A1 (en) | 2017-06-02 | 2020-01-30 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| US20210161883A1 (en) * | 2017-07-10 | 2021-06-03 | Constellation Pharmaceuticals, Inc. | Ezh2 inhibitor-induced gene expression |
| JP7399079B2 (ja) | 2017-09-05 | 2023-12-15 | エピザイム，インコーポレイティド | 癌を処置するための併用療法 |
| KR20220066892A (ko) * | 2019-08-22 | 2022-05-24 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｔ 세포 요법 및 제스트 동족체 2의 인핸서 (ｅｚｈ2) 억제제의 병용 요법 및 관련 방법 |
| CN110960525A (zh) * | 2019-11-26 | 2020-04-07 | 济南大学 | 新型eed-ezh2相互作用抑制剂的确定和评价 |
| CN110950834A (zh) * | 2019-11-26 | 2020-04-03 | 济南大学 | 新型eed-ezh2相互作用小分子抑制剂的确定和评价 |
| CA3177444A1 (en) * | 2020-05-28 | 2021-12-02 | Carly CAMPBELL | Use of ezh2 inhibitors for treating cancer |
| CN117241802A (zh) * | 2021-04-21 | 2023-12-15 | 新基公司 | 使用2-(2,6-二氧代哌啶-3-基)-4-((2-氟-4-((3-吗啉代氮杂环丁烷-1-基)甲基)苄基)氨基)异吲哚啉-1,3-二酮治疗非霍奇金淋巴瘤的方法 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025230982A1 (en) * | 2024-04-30 | 2025-11-06 | University Of Massachusetts | Itk-ph domain inhibitors and their uses |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| BR112013005806B1 (pt) | 2010-09-10 | 2022-05-10 | Epizyme, Inc | Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2 |
| WO2012118812A2 (en) | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3363B1 (ar) | 2011-04-13 | 2019-03-13 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| US9730925B2 (en) | 2011-09-30 | 2017-08-15 | Glaxomithkline Llc | Methods of treating cancer |
| CA3177515A1 (en) * | 2012-03-12 | 2013-09-19 | Epizyme, Inc. | Inhibitors of human ezh2, and methods of use thereof |
| ES2617379T3 (es) | 2012-04-13 | 2017-06-16 | Epizyme, Inc. | Forma de sal de un inhibidor de histona metiltransferasa EZH2 humana |
| EP2836216B1 (en) | 2012-04-13 | 2022-06-08 | Epizyme, Inc. | Combination therapy for treating cancer |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| BR112015008480A2 (pt) | 2012-10-15 | 2017-07-04 | Epizyme Inc | compostos de benzeno substituído |
| KR20190105669A (ko) | 2012-10-15 | 2019-09-17 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
| US20140120083A1 (en) | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| RU2702908C2 (ru) * | 2012-11-01 | 2019-10-14 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| US20150283142A1 (en) | 2013-03-15 | 2015-10-08 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| EP2934531A4 (en) | 2012-12-19 | 2016-06-15 | Glaxosmithkline Llc | COMBINATION |
| CA2894222A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| CA2894216A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone compounds |
| US20160031907A1 (en) | 2013-03-15 | 2016-02-04 | Epizyme, Inc. | Substituted Benzene Compounds |
| EP2970306A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS |
| KR20160013204A (ko) | 2013-05-30 | 2016-02-03 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절제를 사용하는 암의 치료 |
| US9624205B2 (en) | 2013-07-19 | 2017-04-18 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| EP3022184B1 (en) | 2013-07-19 | 2017-09-27 | Epizyme, Inc. | Substituted benzene compounds |
| CN105593378B (zh) | 2013-10-09 | 2019-09-20 | 豪夫迈·罗氏有限公司 | 用于在人ezh2基因中检测突变的方法和组合物 |
| PE20161273A1 (es) | 2013-10-16 | 2016-12-18 | Epizyme Inc | Forma salina de hidrocloruro para la inhibicion de ezh2 |
| WO2015058125A1 (en) | 2013-10-18 | 2015-04-23 | Epizyme, Inc. | Method of treating cancer |
| MX373187B (es) | 2013-12-06 | 2020-04-13 | Epizyme Inc | Terapia de combinación para tratar cáncer. |
| EA038337B1 (ru) | 2014-06-17 | 2021-08-11 | Эпизим, Инк. | Ингибиторы ezh2 для лечения лимфомы |
| BR112017009440A2 (pt) | 2014-11-06 | 2017-12-19 | Dana Farber Cancer Inst Inc | uso de composições que modulam a estrutura de cromatina quanto à doença do enxerto versus hospedeiro (gvhd) |
| KR102964530B1 (ko) | 2014-11-17 | 2026-05-13 | 에피자임, 인코포레이티드 | 암을 치료하기 위한 방법 |
| JP6544507B2 (ja) | 2015-02-09 | 2019-07-17 | 日本精機株式会社 | ヘッドアップディスプレイ装置 |
| EA201890009A1 (ru) | 2015-06-10 | 2018-07-31 | Эпизайм, Инк. | Ингибиторы ezh2 для лечения лимфомы |
| KR20170095656A (ko) | 2016-02-15 | 2017-08-23 | 동부대우전자 주식회사 | 방열구조를 갖는 세탁기 |
-
2015
- 2015-06-17 EA EA201692285A patent/EA038337B1/ru unknown
- 2015-06-17 IL IL309539A patent/IL309539A/en unknown
- 2015-06-17 DK DK15809540.6T patent/DK3157527T3/da active
- 2015-06-17 CN CN201580036258.XA patent/CN106999498B/zh active Active
- 2015-06-17 CA CA2952074A patent/CA2952074C/en active Active
- 2015-06-17 JP JP2016573564A patent/JP6779793B2/ja active Active
- 2015-06-17 BR BR112016029492A patent/BR112016029492A2/pt not_active Application Discontinuation
- 2015-06-17 FI FIEP15809540.6T patent/FI3157527T3/fi active
- 2015-06-17 AU AU2015277139A patent/AU2015277139A1/en not_active Abandoned
- 2015-06-17 SG SG11201610273VA patent/SG11201610273VA/en unknown
- 2015-06-17 KR KR1020177000760A patent/KR102497728B1/ko active Active
- 2015-06-17 IL IL285201A patent/IL285201B2/en unknown
- 2015-06-17 PL PL15809540.6T patent/PL3157527T3/pl unknown
- 2015-06-17 WO PCT/US2015/036310 patent/WO2015195848A1/en not_active Ceased
- 2015-06-17 KR KR1020237004113A patent/KR20230031963A/ko not_active Ceased
- 2015-06-17 EP EP23174369.1A patent/EP4252851A3/en active Pending
- 2015-06-17 MX MX2021007651A patent/MX2021007651A/es unknown
- 2015-06-17 CN CN202110532717.0A patent/CN113289022A/zh active Pending
- 2015-06-17 HU HUE15809540A patent/HUE062158T2/hu unknown
- 2015-06-17 LT LTEPPCT/US2015/036310T patent/LT3157527T/lt unknown
- 2015-06-17 SG SG10201811128RA patent/SG10201811128RA/en unknown
- 2015-06-17 SI SI201531951T patent/SI3157527T1/sl unknown
- 2015-06-17 EP EP15809540.6A patent/EP3157527B1/en active Active
- 2015-06-17 US US15/319,535 patent/US10166238B2/en active Active
- 2015-06-17 ES ES15809540T patent/ES2948442T3/es active Active
- 2015-06-17 MX MX2016016744A patent/MX383866B/es unknown
- 2015-06-17 PT PT158095406T patent/PT3157527T/pt unknown
-
2016
- 2016-12-07 IL IL249438A patent/IL249438A0/en unknown
-
2018
- 2018-11-06 US US16/181,747 patent/US20190175604A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,835 patent/US20200022987A1/en not_active Abandoned
-
2020
- 2020-03-04 US US16/808,513 patent/US11642347B2/en active Active
- 2020-09-28 AU AU2020244382A patent/AU2020244382B2/en not_active Ceased
-
2022
- 2022-11-03 AU AU2022263523A patent/AU2022263523A1/en not_active Abandoned
-
2023
- 2023-03-23 US US18/188,716 patent/US20240058348A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2883751C (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
| MX2021002886A (es) | Terapia de combinacion para el tratamiento de cancer de mama triple negativo. | |
| ZA202202361B (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
| WO2018102687A3 (en) | Combination therapy for treating cancer | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| BR112018070017A2 (pt) | métodos de tratamento de cânceres pediátricos | |
| MX2021002321A (es) | Nuevos metodos. | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
| EA200970595A1 (ru) | Производные замещенных индазолов, активные в качестве ингибиторов киназ | |
| MX2021011563A (es) | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. | |
| MX378263B (es) | Terapia de combinación para el tratamiento del cáncer. | |
| EA201391286A1 (ru) | Лечение солидных опухолей | |
| WO2015095834A3 (en) | Cancer treatments using erk1/2 and bcl-2 family inhibitors | |
| IN2015DN00376A (enExample) | ||
| MX337614B (es) | Tratamiento de lupus nefritis usando laquinimod. | |
| PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
| EA201590166A8 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| MX2017000612A (es) | Inhibidores de tirosina quinasa del bazo (syk). | |
| MX2023001468A (es) | Tratamiento de cancer de prostata. | |
| RU2020109376A (ru) | Применение антагонистов рецептора ep4 для лечения nash- ассоциированного рака печени | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| CL2023000296A1 (es) | Uso de dexpramipexol para el tratamiento del asma moderado a grave |